Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $97.6, a high estimate of $103.00, and a low estimate of $93.00. This upward trend ...

StockNews.com lowered shares of Globus Medical (NYSE:GMED – Free Report) from a buy rating to a hold rating in a research report sent to investors on Wednesday morning. Several other research analysts ...

According to Benzinga Pro, Globus Medical's peer group average for short interest as a percentage of float is 4.18%, which means the company has less short interest than most of its peers. Did you ...

Globus Medical (NYSE:GMED – Get Free Report)‘s stock had its “hold” rating restated by equities researchers at Needham & ...

Net income rose by 77% to $26.5 million, highlighting significant growth. Globus Medical's results underscore a strong quarter, with effective execution of strategic initiatives, notably the full ...

Medical device company Globus Medical (NYSE:GMED) reported Q4 CY2024 results beating Wall Street’s revenue expectations , with sales up 6.6% year on year to $657.3 million. The company expects ...

Globus Medical closed 2024 on a strong note with record financial performance, driven by sales growth, innovative product launches, and strategic acquisitions. The integration of Nevro Corporation ...

Try Now>> See today’s best-performing stocks on TipRanks >> Read More on GMED: Globus Medical NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

AUDUBON, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it is scheduled to participate in the Canaccord ...